SCHEMBL21151787

SCHEMBL21151787

CC(C)(C)OC(=O)N1CCC2(C1)NC(=O)N(c1ccccc1)C2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.54
GPR119 Q8TDV5 1/20 0.46
RORC P51449 1/20 0.44
SCD5 Q86SK9 1/20 0.44
CCR5 P51681 2/20 0.43
CYP11B2 P19099 1/20 0.43
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.41
ATM Q13315 1/20 0.41
NPC1L1 Q9UHC9 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
TACR1 P25103 2/20 0.41
MAPK1 P28482 1/20 0.40
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
USP2 O75604 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19534281 0.93 GPR119 (0.51) USP30GPR119CCR5TSHRALOX15
SCHEMBL31270940 0.89 RORC (0.46) USP30GPR119RORCCYP11B2TACR1
SCHEMBL31277323 0.87 USP30 (0.49) USP30GPR119RORCSCD5CYP11B2
SCHEMBL27332238 0.87 USP30 (0.49) USP30GPR119RORCSCD5CYP11B2
SCHEMBL23288897 0.84 ITGB3 (0.46) USP30GPR119CCR5TSHRALOX15
SCHEMBL31537258 0.83 POLB (0.56) USP30GPR119TACR1ITGB3ITGA2B
SCHEMBL31270993 0.82 USP30 (0.43) USP30GPR119RORCSCD5CYP11B2
SCHEMBL31271700 0.82 POLB (0.43) USP30GPR119RORCTACR1
SCHEMBL21150843 0.81 AR (0.46) USP30GPR119TACR1ITGB3ITGA2B
SCHEMBL21151418 0.81 TACR1 (0.45) USP30GPR119TACR1MAPK1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B USP30 4473/4885GPR119 926/4885RORC 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.